Screening high-risk Veterans for cirrhosis: taking a stepwise population health approach.

Publication date: Jan 29, 2025

Because cirrhosis is often unrecognized, we aimed to develop a stepwise screening algorithm for cirrhosis in the Veterans Health Administration (VHA) and assess this approach’s feasibility and acceptability. VHA hepatology clinicians (“champions”) were invited to participate in a pilot program from June 2020 to October 2022. The VHA Corporate Data Warehouse was queried to identify Veterans with possible undiagnosed cirrhosis using Fibrosis-4 (FIB-4) ≥ 3. 25 and at least one risk factor for liver disease (e. g., obesity), and generate an age-stratified sample. Champions at four sites reviewed charts to confirm eligibility and contacted Veterans to offer further evaluation with elastography. Feasibility was defined as protocol implementation with completion of at least one elastography test and acceptability was defined based on Veteran- and clinician-reported surveys. Participation in the program, patient outcomes, adaptations to the protocol, and implementation barriers were also assessed. Four sites were able to implement the screening protocol. Adaptations included type of outreach (primary care vs. hepatology, phone vs. mail) and type of elastography used. One site chose to refer patients with clear evidence of cirrhosis directly to hepatology (n = 12) rather than to elastography. Key implementation barriers included staffing, primary care provider (PCP) comfort with interpreting and communicating results, and appointment availability during the COVID-19 pandemic. Of 488 patients whose charts were reviewed, 230 were excluded from outreach based on predefined criteria (e. g., advanced cancer, prior or current referral to hepatology). Champions and PCPs attempted to contact 165 of 246 Veterans who were deemed eligible for evaluation with elastography. Among 53 Veterans who completed elastography, 22 (42%) had findings consistent with significant fibrosis and were referred to hepatology. Clinicians and Veterans reported high acceptability of the program on surveys (80% of Veterans who completed survey). This pilot demonstrated the feasibility, acceptability, and challenges of a multisite approach to cirrhosis screening.

Open Access PDF

Concepts Keywords
Cancer Cirrhosis
June Elastography
October Primary care
Pilot Screening
Veterans Veterans

Semantics

Type Source Name
disease MESH cirrhosis
disease IDO algorithm
disease MESH liver disease
disease MESH obesity
disease IDO site
drug DRUGBANK Phencyclidine
disease MESH COVID-19 pandemic
disease MESH cancer
pathway REACTOME Reproduction
disease MESH hepatocellular carcinoma
pathway KEGG Hepatocellular carcinoma
disease MESH complications
disease IDO blood
drug DRUGBANK Alpha-Linolenic Acid
drug DRUGBANK Methionine
drug DRUGBANK Tretamine
drug DRUGBANK Trestolone
disease MESH diabetes mellitus
drug DRUGBANK Ethanol
disease MESH hepatitis
disease MESH congestive heart failure
disease MESH cytopenia
disease MESH contraindications
disease MESH ascites
disease MESH anasarca
disease IDO process
disease IDO facility
disease MESH panic
disease MESH Comorbidity
disease MESH death
disease MESH weight loss
drug DRUGBANK Etoperidone
disease MESH metabolic syndrome
disease MESH etiology
disease MESH tic
disease MESH infection
drug DRUGBANK Spinosad
disease IDO quality
disease MESH liver fibrosis
disease MESH coinfection
disease MESH NAFLD
pathway REACTOME Translation
disease MESH morbid obesity
disease MESH peripheral neuropathy
disease IDO intervention

Original Article

(Visited 1 times, 1 visits today)